To Evaluate the Efficacy and Safety of LuminoMark Injection in Patients With Nonpalpable Breast Lesions

NCT03743259 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

44

Enrollment

INDUSTRY

Sponsor class

Conditions

Breast Diseases

Interventions

DRUG: LuminoMark inj. 0.1mL
DRUG: LuminoMark inj. 0.2mL
DRUG: Charcotrace Inj.

Sponsor

Hanlim Pharm. Co., Ltd.